array(13) { ["code"]=> string(2) "de" ["id"]=> string(1) "3" ["native_name"]=> string(7) "Germany" ["major"]=> string(1) "1" ["active"]=> string(1) "1" ["default_locale"]=> string(5) "de_DE" ["encode_url"]=> string(1) "0" ["tag"]=> string(5) "de-de" ["missing"]=> int(0) ["translated_name"]=> string(7) "Germany" ["url"]=> string(224) "https://www.prosigna.com/de/resource/analytical-validation-of-the-pam50-based-prosigna-breast-cancer-prognostic-gene-signature-assay-and-ncounter-analysis-system-using-formalin-fixed-paraffin-embedded-breast-tumor-specimens/" ["country_flag_url"]=> string(87) "https://www.prosigna.com/wp-content/plugins/sitepress-multilingual-cms/res/flags/de.png" ["language_code"]=> string(2) "de" } native: Germany
translated: Germany
IN the US OUTSIDE the US
KONTAKT

Kontaktieren Sie uns heute

Montag bis Freitag, 5:30 Uhr bis 17:00 Uhr (PST, CET +9)

Telefon: +1.650.243.6335

Fax: +1.650.243.6388

info@prosigna.com

Live-Webinar – 16. Mai 2023 um 18:00 Uhr: „Wie können molekulare Subtypen therapeutische Entscheidungen leiten?“
JETZT REGISTRIEREN